近期，我们在国际上首次系统地提出了艾滋病病毒（HIV）蛋白灭活剂的概念，并创新性地研发了第一代蛋白灭活剂，引起了国际上的广泛关注。HIV蛋白灭活剂与目前所有临床上使用的抗HIV药物不同，它不仅可在病毒入侵靶细胞时起到抑制作用，而且可在没有靶细胞存在的情况下主动地灭活病毒，相对于传统的抑制剂和化合物去污剂其具有高特异性、高活性、低毒性、高利用率的显著优势，非常有潜力开发成为新型的抗HIV药物。在本课题中，我们将紧密围绕蛋白药物研究的国际前沿趋势，首次利用国际先进的拟抗体长效化技术来解决第一代蛋白灭活剂半衰期短、成药性不佳的缺点，并对所设计的新型长效化灭活剂的作用靶点、抑制机制、灭活机制及长效机制等展开深入的研究，揭示其作用机理。目前，该研究在国际上尚未见报导。本课题的顺利开展将为解决HIV蛋白药物的研究瓶颈提供有效思路，并为研发具有中国自主知识产权的新型HIV药物提供重要的理论和实验基础。

Recently, we put forward systematically the concept of HIV protein inactivator and develop the first HIV protein inactivator drug in the international community, raising widespread concern. Different from all the clinical anti-HIV drugs, HIV protein inactivator not only plays an inhibitory effect on the virus entry, also inactivate the free-virus without the existence of the target cells. Compared to traditional inhibitors and organic compounds detergents, it has the significant advantage of high specificity, potent activity, low toxicity, and high efficiency; all these makes it has the great potential to further develop as a brand new type of anti-HIV drugs. In this project, we will focus on the international forefront trends of protein drug research, use the advanced international monobody long-term technology for the first time to solve the shortcomings-short half-life and low druggability-of the first generation protein inactivator developed in preparatory research work, and perform the intensive study based on the target of the designed long-term inactivator, virus inhibitory mechanism, inactivation mechanism and long-term mechanism to reveals its mechanism of action. To date, the application of monobody long-term technology in HIV protein drugs has not peen reported. This application will possess apparent innovativeness, will bring a breakthrough in this field, and accelerate transformation, providing important theoretical and experimental basis for the development of new anti-HIV drugs with independent intellectual property rights of China.